½ÃÀ庸°í¼­
»óǰÄÚµå
1597911

¼¼°èÀÇ ¾Ï ¸é¿ª¿ä¹ý ½ÃÀå : Ä¡·á¹ýÀÇ °æÀï - Ä¡·á¹ýº°, ¾Ïº°, °í°´º° ¸é¿ª¾Ï Ä¡·á ½ÃÀå ¿¹Ãø : ÁÖ¿ä ÄÁ¼³ÅÏÆ® °¡À̵å ÷ºÎ(2025-2029³â)

Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2025 to 2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Howe Sound Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 262 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾ÏÄ¡·á¿¡ À־ÀÇ Çõ¸íÀÌ ÁøÇàÁßÀÔ´Ï´Ù. ½ÅüÀÇ ÀÚ¿¬ ¸é¿ª ¹æ¾î¸¦ ÀÌ¿ëÇÑ »õ·Î¿î Ä¡·á¹ýÀÌ, °ú°Å ¾ø´Â ¼º°øÀ» °ÅµÎ°í ÀÖ½À´Ï´Ù. ±ØÀûÀÎ ¼ºÀåÀ» ÀÌ·ç·Á°í ÇÕ´Ï´Ù.

º» º¸°í¼­´Â ¼¼°èÀÇ ¾Ï ¸é¿ª¿ä¹ý ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² Ä¡·á¹ýº°, ¾Ïº°, °í°´º° µ¿Çâ ¹× ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå °¡À̵å

Á¦2Àå ¼Ò°³¿Í ½ÃÀå Á¤ÀÇ

  • ¾Ï ¸é¿ª¿ä¹ýÀ̶õ ¹«¾ùÀΰ¡
  • ¸é¿ª¿ä¹ý- ´Ù°¡¿À´Â Ä¡·á¹ý
  • ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»ç ¹æ¹ý
  • ¹Ì±¹ÀÇ ÀÇ·á ½ÃÀå°ú ÀǾàǰ ÁöÃâ- Àü¸Á

Á¦3Àå ¸é¿ª¿ä¹ý- ¸é¿ª±â¼ú °¡À̵å

  • ¸é¿ª ½Ã½ºÅÛ
  • ¸é¿ªÁ¾¾çÇÐ ±â¼ú

Á¦4Àå ¾÷°è °³¿ä

  • ½ÃÀå ÁøÃâ±â¾÷ - ¿ªÇÒ°ú ¿µÇâ

Á¦5Àå ½ÃÀå µ¿Çâ

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • Ä¡·á ±â¼ú °³¹ß

Á¦6Àå ¾Ï ¸é¿ª¿ä¹ýÀÇ ÃÖ±Ù µ¿Çâ

Á¦7Àå ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • AbbVie
  • Achilles Therapeutics
  • Acumen Pharmaceuticals
  • Adagene
  • Adaptimmune Therapeutics
  • Adicet Bio
  • ALX Oncology Holdings
  • Ambrx Biopharma
  • Amgen
  • Apexigen
  • Arcus Biosciences
  • argenx
  • AstraZeneca
  • Atreca
  • Avalo Therapeutics
  • Avid Bioservices
  • Bavarian Nordic
  • BioAtla
  • Biogen Inc.
  • BioNTech
  • Bolt Biotherapeutics
  • Bristol-Myers Squibb
  • Candel Therapeutics
  • Caribou Biosciences
  • Celldex Therapeutics
  • Checkpoint Therapeutics
  • Chinook Therapeutics
  • Corvus Pharmaceuticals
  • Cullinan Oncology
  • Eli Lilly
  • EOM Pharmaceuticals
  • Evaxion Biotech
  • Genenta Science
  • Gilead Sciences
  • Gracell Biotechnologies
  • Greenwich LifeSciences
  • Gritstone bio
  • Harpoon Therapeutics
  • ImmunityBio
  • Immunocore Holdings
  • Immunome
  • IMV Inc
  • Incyte
  • Indaptus Therapeutics
  • Instil Bio
  • Iovance Biotherapeutics
  • Johnson & Johnson
  • Marker Therapeutics
  • Medicenna Therapeutics
  • Merck & Co.
  • Merus
  • Moderna
  • Mustang Bio
  • Nanobiotix
  • Neoleukin Therapeutics
  • Novartis
  • Novavax
  • Oncorus
  • PDS Biotechnology
  • Pfizer
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Sensei Biotherapeutics
  • Senti Biosciences
  • Surface Oncology
  • Takeda Pharmaceutical
  • TC Biopharm
  • ThermoGenesis Holdings
  • UroGen Pharma
  • Werewolf Therapeutics
  • Xilio Therapeutics
  • Zymeworks

Á¦8Àå ¼¼°èÀÇ ¾Ï ¸é¿ª¿ä¹ý ½ÃÀå

  • ¼¼°è ½ÃÀå °³¿ä, ±¹°¡º°
  • ¼¼°è ½ÃÀå °³¿ä, Ä¡·áº°
  • ¼¼°è ½ÃÀå °³¿ä, ¾Ïº°
  • ¼¼°è ½ÃÀå °³¿ä, °í°´º°

Á¦9Àå ¼¼°èÀÇ ¾Ï ¸é¿ª¿ä¹ý ½ÃÀå-Ä¡·áº°

  • MAB
  • »çÀÌÅäÄ«ÀÎ
  • ¹é½Å
  • ¼¿ º£À̽º
  • ¾ïÁ¦Á¦/ÀÛ¿ëÁ¦
  • ±âŸ

Á¦10Àå ¼¼°èÀÇ ¾Ï ¸é¿ª¿ä¹ý ½ÃÀå-¾Ïº°

  • À¯¹æ¾Ï
  • ´ëÀå¾Ï
  • °æºÎ¾Ï
  • Æó¾Ï
  • Àü¾Ï »óÅÂ
  • Àü¸³¼±¾Ï
  • Èæ»öÁ¾
  • Ç÷¾×¾Ï
  • ±âŸ

Á¦11Àå ¼¼°èÀÇ ¾Ï ¸é¿ª¿ä¹ý ½ÃÀå-°í°´º°

  • Á¦¾àȸ»ç
  • Ŭ¸®´Ð
  • ±âŸ

Á¦12Àå ºÎ·Ï

JHS 24.12.04

Report Overview:

Are cures for cancer in sight? What is the opportunity in this market? What companies are poised to benefit? Is disruption a possibility? Find out in this comprehensive report.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. CAR - T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon.

Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out to 2027.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

  • 1.1. Situation Analysis
  • 1.2. Guide for Executives and Marketing Staff
  • 1.3. Guide for Investment Analysts and Management Consultants

2. Introduction and Market Definition

  • 2.1. What is Cancer Immunotherapy?
  • 2.2. Immunotherapy - the looming cures
  • 2.3. Market Definition
    • 2.3.1. Market Size
    • 2.3.2. Currency
    • 2.3.3. Years
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. U.S. Medical Market and Pharmceutical Spending - Perspective
    • 2.5.1. Global Expenditures for Medicines

3. Immunotherapy - Guide to Immune Technologies

  • 3.1. The Immune System
    • 3.1.1. Innate immune system
      • 3.1.1.1. Surface barriers
      • 3.1.1.2. Inflammation
      • 3.1.1.3. Complement system
      • 3.1.1.4. Cellular barriers
      • 3.1.1.5. Natural killer cells
    • 3.1.2. Adaptive immune system
      • 3.1.2.1. Lymphocytes
      • 3.1.2.2. Killer T cells
      • 3.1.2.3. Helper T cells
      • 3.1.2.4. Gamma delta T cells
      • 3.1.2.5. B lymphocytes and antibodies
    • 3.1.3. Tumor immunology - the immune surveillance system
  • 3.2. Immuno Oncology Technologies
    • 3.2.1. Monoclonal Antibodies
      • 3.2.1.1. Outlook for Monoclonal Antibodies
      • 3.2.1.2. Companies with Monoclonal Antibodies in their Pipeline
    • 3.2.2. Cancer vaccines
      • 3.2.2.1. Outlook for Cancer Vaccines
      • 3.2.2.2. Companies with Cancer Vaccines in their Pipeline
    • 3.2.3. Cytokines
      • 3.2.3.1. Outlook for Cytokines
      • 3.2.3.2. Companies with Cytokines in their Pipeline
    • 3.2.4. Cell Based Therapies
      • 3.2.4.1. Outlook for Cell Based Therapies
      • 3.2.4.2. Companies with Cell Based Therapies in their Pipeline
    • 3.2.5. Inhibitors/Agonists
      • 3.2.5.1. Outlook for Inhibitors/Agonists
      • 3.2.5.2. Companies with Inhibitors/Agonists in their Pipeline
    • 3.2.6. Antibody Drug Conjugates
      • 3.2.6.1. Outlook for Antibody Drug Conjugates
      • 3.2.6.2. Companies with Antibody Drug Conjugates in their Pipeline
    • 3.2.7. Others
      • 3.2.7.1. Outlook for Other Therapeutics
      • 3.2.7.2. Companies with Viral Therapeutics in their Pipeline
      • 3.2.7.3. Companies with Other Therapeutics in their Pipeline

4. Industry Overview

  • 4.1. Market Players - Roles & Impacts
    • 4.1.1. Drug manufacturers - Larger/pharmaceutical
    • 4.1.2. Drug manufacturers - Generic
    • 4.1.3. Contract Research and Manufacturing
    • 4.1.4. In Vitro Diagnostics Industry
    • 4.1.5. Drug Marketing Companies
    • 4.1.6. Biotechnology Companies
    • 4.1.7. Regulatory Bodies

5. Market Trends

  • 5.1. Factors Driving Growth
    • 5.1.1. Outcome potential
    • 5.1.2. Fast tracking
    • 5.1.3. Funding
    • 5.1.4. Technology Environment
    • 5.1.5. Target Solutions
  • 5.2. Factors Limiting Growth
    • 5.2.1. Cost of Treatment
    • 5.2.2. Clinical Trials Role
    • 5.2.3. Combinations
    • 5.2.4. Protocols
  • 5.3. Therapeutic Technology Development
    • 5.3.1. Combinations - Issues and Complexity
    • 5.3.2. Preference for a drug
    • 5.3.3. Problems of Immunity Engineering
    • 5.3.4. The Role of Cost
    • 5.3.5. The Disruption Dynamic
    • 5.3.6. CAR-T Cell Therapy
    • 5.3.7. The Next Five Years

6. Cancer Immunotherapy Recent Developments

  • 6.1. Recent Developments - Importance and How to Use This Section
    • 6.1.1. Importance of These Developments
    • 6.1.2. How to Use This Section
  • 6.2. Merck, buys into new kind of cancer immunotherapy
  • 6.3. Immunotherapy after surgery
  • 6.4. Anti-CTLA-4 nanobody a promising approach
  • 6.5. Continued Success with Immunotherapy in Melanoma
  • 6.6. AC Immune Receives FDA Fast Track Designation
  • 6.7. LTZ Announces Financing
  • 6.8. Immunotherapy for Cancer Overview
  • 6.9. Implantable device shrinks pancreatic tumors
  • 6.10. mRNA Vaccine And Immunotherapy Reduce Melanoma Recurrence
  • 6.11. Towards a Universal Cancer Immunotherapy
  • 6.12. New Strategy May Improve T-Cell Therapy in Solid Tumors
  • 6.13. Immunotherapy linked to increase in Medicare spending
  • 6.14. Immunotherapy Effective with Ovarian Cancer
  • 6.15. Cancer Immunotherapy Granted Fast Track

7. Profiles of Key Immunotherapy Companies

  • 7.1. AbbVie
  • 7.2. Achilles Therapeutics
  • 7.3. Acumen Pharmaceuticals
  • 7.4. Adagene
  • 7.5. Adaptimmune Therapeutics
  • 7.6. Adicet Bio
  • 7.7. ALX Oncology Holdings
  • 7.8. Ambrx Biopharma
  • 7.9. Amgen
  • 7.10. Apexigen
  • 7.11. Arcus Biosciences
  • 7.12. argenx
  • 7.13. AstraZeneca
  • 7.14. Atreca
  • 7.15. Avalo Therapeutics
  • 7.16. Avid Bioservices
  • 7.17. Bavarian Nordic
  • 7.18. BioAtla
  • 7.19. Biogen Inc.
  • 7.20. BioNTech
  • 7.21. Bolt Biotherapeutics
  • 7.22. Bristol-Myers Squibb
  • 7.23. Candel Therapeutics
  • 7.24. Caribou Biosciences
  • 7.25. Celldex Therapeutics
  • 7.26. Checkpoint Therapeutics
  • 7.27. Chinook Therapeutics
  • 7.28. Corvus Pharmaceuticals
  • 7.29. Cullinan Oncology
  • 7.30. Eli Lilly
  • 7.31. EOM Pharmaceuticals
  • 7.32. Evaxion Biotech
  • 7.33. Genenta Science
  • 7.34. Gilead Sciences
  • 7.35. Gracell Biotechnologies
  • 7.36. Greenwich LifeSciences
  • 7.37. Gritstone bio
  • 7.38. Harpoon Therapeutics
  • 7.39. ImmunityBio
  • 7.40. Immunocore Holdings
  • 7.41. Immunome
  • 7.42. IMV Inc
  • 7.43. Incyte
  • 7.44. Indaptus Therapeutics
  • 7.45. Instil Bio
  • 7.46. Iovance Biotherapeutics
  • 7.47. Johnson & Johnson
  • 7.48. Marker Therapeutics
  • 7.49. Medicenna Therapeutics
  • 7.50. Merck & Co.
  • 7.51. Merus
  • 7.52. Moderna
  • 7.53. Mustang Bio
  • 7.54. Nanobiotix
  • 7.55. Neoleukin Therapeutics
  • 7.56. Novartis
  • 7.57. Novavax
  • 7.58. Oncorus
  • 7.59. PDS Biotechnology
  • 7.60. Pfizer
  • 7.61. Regeneron Pharmaceuticals
  • 7.62. Roche
  • 7.63. Sanofi
  • 7.64. Sensei Biotherapeutics
  • 7.65. Senti Biosciences
  • 7.66. Surface Oncology
  • 7.67. Takeda Pharmaceutical
  • 7.68. TC Biopharm
  • 7.69. ThermoGenesis Holdings
  • 7.70. UroGen Pharma
  • 7.71. Werewolf Therapeutics
  • 7.72. Xilio Therapeutics
  • 7.73. Zymeworks

8. The Global Market for Immuno-Oncology Therapeutics

  • 8.1. Global Market Overview by Country
    • 8.1.1. Table - Global Market by Country
    • 8.1.2. Chart - Global Market by Country
  • 8.2. Global Market by Therapy - Overview
    • 8.2.1. Table - Global Market by Therapy
    • 8.2.2. Chart - Global Market by Therapy - Base/Final Year Comparison
    • 8.2.3. Chart - Global Market by Therapy - Base Year
    • 8.2.4. Chart - Global Market by Therapy - End Year
    • 8.2.5. Chart - Global Market by Therapy - Share by Year
    • 8.2.6. Chart - Global Market by Therapy - Segments Growth
  • 8.3. Global Market by Cancer - Overview
    • 8.3.1. Table - Global Market by Cancer
    • 8.3.2. Chart - Global Market by Cancer - Base/Final Year Comparison
    • 8.3.3. Chart - Global Market by Cancer - Base Year
    • 8.3.4. Chart - Global Market by Cancer - End Year
    • 8.3.5. Chart - Global Market by Cancer - Share by Year
    • 8.3.6. Chart - Global Market by Cancer - Segments Growth
  • 8.4. Global Market by Customer - Overview
    • 8.4.1. Table - Global Market by Customer
    • 8.4.2. Chart - Global Market by Customer - Base/Final Year Comparison
    • 8.4.3. Chart - Global Market by Customer - Base Year
    • 8.4.4. Chart - Global Market by Customer - End Year
    • 8.4.5. Chart - Global Market by Customer - Share by Year
    • 8.4.6. Chart - Global Market by Customer - Segments Growth

9. Global Immuno-Oncology Therapy Markets - By Therapy

  • 9.1. MAB
    • 9.1.1. Table MAB - by Country
    • 9.1.2. Chart - MAB Growth
  • 9.2. Cytokine
    • 9.2.1. Table Cytokine - by Country
    • 9.2.2. Chart - Cytokine Growth
  • 9.3. Vaccine
    • 9.3.1. Table Vaccine - by Country
    • 9.3.2. Chart - Vaccine Growth
  • 9.4. Cell Based
    • 9.4.1. Table Cell Based - by Country
    • 9.4.2. Chart - Cell Based Growth
  • 9.5. Inhibitor/Agonist
    • 9.5.1. Table Inhibitor/Agonist - by Country
    • 9.5.2. Chart - Inhibitor/Agonist Growth
  • 9.6. Other IO Therapy
    • 9.6.1. Table Other IO Therapy - by Country
    • 9.6.2. Chart - Other IO Therapy Growth

10. Global Immuno-Oncology Therapeutic Markets - By Cancer

  • 10.1. Breast
    • 10.1.1. Table Breast - by Country
    • 10.1.2. Chart - Breast Growth
  • 10.2. ColoRectal
    • 10.2.1. Table ColoRectal - by Country
    • 10.2.2. Chart - ColoRectal Growth
  • 10.3. Cervical
    • 10.3.1. Table Cervical - by Country
    • 10.3.2. Chart - Cervical Growth
  • 10.4. Lung
    • 10.4.1. Table Lung - by Country
    • 10.4.2. Chart - Lung Growth
  • 10.5. Precancer
    • 10.5.1. Table Precancer - by Country
    • 10.5.2. Chart - Precancer Growth
  • 10.6. Prostate
    • 10.6.1. Table Prostate - by Country
    • 10.6.2. Chart - Prostate Growth
  • 10.7. Melanoma
    • 10.7.1. Table Melanoma - by Country
    • 10.7.2. Chart - Melanoma Growth
  • 10.8. Blood
    • 10.8.1. Table Blood - by Country
    • 10.8.2. Chart - Blood Growth
  • 10.9. Other Cancer
    • 10.9.1. Table Other Cancer - by Country
    • 10.9.2. Chart - Other Cancer Growth

11. Global Immuno-Oncology Therapeutic Markets - By Customer

  • 11.1. Pharma
    • 11.1.1. Table Pharma - by Country
    • 11.1.2. Chart - Pharma Growth
  • 11.2. Clinic
    • 11.2.1. Table Clinic - by Country
    • 11.2.2. Chart - Clinic Growth
  • 11.3. Other Customer
    • 11.3.1. Table Other Customer - by Country
    • 11.3.2. Chart - Other Customer Growth

12. Appendices

  • 12.1. FDA Cancer Drug Approvals by Year
  • 12.2. Clinical Trials Started
  • 12.3. Prevalence of Cancer Treatments
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦